436 related articles for article (PubMed ID: 33039466)
1. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer.
Dreyer SB; Upstill-Goddard R; Paulus-Hock V; Paris C; Lampraki EM; Dray E; Serrels B; Caligiuri G; Rebus S; Plenker D; Galluzzo Z; Brunton H; Cunningham R; Tesson M; Nourse C; Bailey UM; Jones M; Moran-Jones K; Wright DW; Duthie F; Oien K; Evers L; McKay CJ; McGregor GA; Gulati A; Brough R; Bajrami I; Pettitt S; Dziubinski ML; Candido J; Balkwill F; Barry ST; Grützmann R; Rahib L; ; ; Johns A; Pajic M; Froeling FEM; Beer P; Musgrove EA; Petersen GM; Ashworth A; Frame MC; Crawford HC; Simeone DM; Lord C; Mukhopadhyay D; Pilarsky C; Tuveson DA; Cooke SL; Jamieson NB; Morton JP; Sansom OJ; Bailey PJ; Biankin AV; Chang DK
Gastroenterology; 2021 Jan; 160(1):362-377.e13. PubMed ID: 33039466
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Cancer Res Treat; 2020 Jan; 52(1):149-166. PubMed ID: 31291716
[TBL] [Abstract][Full Text] [Related]
4. BRCA mutations in pancreatic cancer and progress in their targeting.
Alkassis S; Yazdanpanah O; Philip PA
Expert Opin Ther Targets; 2021 Jul; 25(7):547-557. PubMed ID: 34289788
[No Abstract] [Full Text] [Related]
5. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
6. DNA damage response and repair in pancreatic cancer development and therapy.
Rahnamay Farnood P; Danesh Pazhooh R; Asemi Z; Yousefi B
DNA Repair (Amst); 2021 Jul; 103():103116. PubMed ID: 33882393
[TBL] [Abstract][Full Text] [Related]
7. Harnessing DNA Replication Stress for Novel Cancer Therapy.
Zhu H; Swami U; Preet R; Zhang J
Genes (Basel); 2020 Aug; 11(9):. PubMed ID: 32854236
[TBL] [Abstract][Full Text] [Related]
8. DNA damage response and prostate cancer: defects, regulation and therapeutic implications.
Karanika S; Karantanos T; Li L; Corn PG; Thompson TC
Oncogene; 2015 May; 34(22):2815-22. PubMed ID: 25132269
[TBL] [Abstract][Full Text] [Related]
9. An insight into understanding the coupling between homologous recombination mediated DNA repair and chromatin remodeling mechanisms in plant genome: an update.
Banerjee S; Roy S
Cell Cycle; 2021 Sep; 20(18):1760-1784. PubMed ID: 34437813
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
11. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
12. Multiple Perspectives Reveal the Role of DNA Damage Repair Genes in the Molecular Classification and Prognosis of Pancreatic Adenocarcinoma.
Li Y; Zhang K; Peng L; Chen L; Gao H; Chen H
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142142
[TBL] [Abstract][Full Text] [Related]
13. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
14. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.
Gout J; Perkhofer L; Morawe M; Arnold F; Ihle M; Biber S; Lange S; Roger E; Kraus JM; Stifter K; Hahn SA; Zamperone A; Engleitner T; Müller M; Walter K; Rodriguez-Aznar E; Sainz B; Hermann PC; Hessmann E; Müller S; Azoitei N; Lechel A; Liebau S; Wagner M; Simeone DM; Kestler HA; Seufferlein T; Wiesmüller L; Rad R; Frappart PO; Kleger A
Gut; 2021 Apr; 70(4):743-760. PubMed ID: 32873698
[TBL] [Abstract][Full Text] [Related]
15. PARI overexpression promotes genomic instability and pancreatic tumorigenesis.
O'Connor KW; Dejsuphong D; Park E; Nicolae CM; Kimmelman AC; D'Andrea AD; Moldovan GL
Cancer Res; 2013 Apr; 73(8):2529-39. PubMed ID: 23436799
[TBL] [Abstract][Full Text] [Related]
16. The Adenovirus E4orf4 Protein Provides a Novel Mechanism for Inhibition of the DNA Damage Response.
Brestovitsky A; Nebenzahl-Sharon K; Kechker P; Sharf R; Kleinberger T
PLoS Pathog; 2016 Feb; 12(2):e1005420. PubMed ID: 26867009
[TBL] [Abstract][Full Text] [Related]
17. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
[TBL] [Abstract][Full Text] [Related]
18. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
19. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
[TBL] [Abstract][Full Text] [Related]
20. Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer.
Durinikova E; Reilly NM; Buzo K; Mariella E; Chilà R; Lorenzato A; Dias JML; Grasso G; Pisati F; Lamba S; Corti G; Degasperi A; Cancelliere C; Mauri G; Andrei P; Linnebacher M; Marsoni S; Siena S; Sartore-Bianchi A; Nik-Zainal S; Di Nicolantonio F; Bardelli A; Arena S
Clin Cancer Res; 2022 Sep; 28(17):3874-3889. PubMed ID: 35881546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]